10 December 2018
  • Share

We may be approaching the end of the year, but the saga of patents for plant related inventions at the EPO continues to develop.  The Administrative Council of the EPO had tried to introduce some legal certainty in this area last year, by introducing new Rule 28(2) into the Implementing Regulations of the European Patent Convention (EPC).  That new rule prohibits the grant of patents for plants or animals obtained exclusively by essentially biological processes, such as crossing and selection.  As we reported at the time, this new rule was not without controversy, because it did not seem to be consistent with the Articles of the EPC.     

In the latest phase of this story, EPO Technical Board of Appeal 3304 noted this inconsistency.  In a hearing on 5 December 2018, they decided that the EPO were wrong to refuse to grant a patent to a new pepper plant as the product of essentially biological processes under Rule 28(2).  According to the EPO (see here), they reasoned that the new rule is not consistent with the EPC and, in the case where there is such a conflict, the Convention prevails over the rules.  In other words, the Board has suggested that new Rule 28(2) is void, and that the EPO should be able to grant patents for plants and animals derived from essentially biological processes.

What does this mean for patentees and applicants?

Well, we’re back to uncertainty, and waiting to see what happens next.  The official written decision of the Board is not expected to issue until the new year, and until then we can only guess at the reasons behind the decision.  It is not clear what the EPO will do in response – we might expect a further stay of proceedings, yet again hitting pause on the examination of cases relating to these inventions.   We might also see the Administrative Council amend the Implementing Regulations again, to remove the offending rule.  In the meantime, the rule remains in place, with a question mark as to whether or not it is void. 

The full decision was released on 5 February 2019.  Now with their reasoning known, we explore whether this decision does bring clarity to those working in this space. Read more here

Fran is a Partner and Patent Attorney at Mewburn Ellis. She works in all patent cycle stages within the life sciences sector – from invention capture, drafting and patent strategy to prosecution and global portfolio management. Fran is a member of our plant variety rights team, having completed the official WIPO course on plant variety protection under the UPOV convention. As such, she has extensive experience dealing with plant-related inventions, including obtaining plant variety rights and entry onto the national list and common catalogue.
Comments

Sign up to our newsletter: Forward - news, insights and feature

Our People

Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.

OUR PEOPLE

Contact Us

We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany.  We’d love to hear from you, so please get in touch.